Multiple Myeloma
MRD testing in multiple myeloma: new technology with promising clinical applications
Determining measurable residual disease (MRD) status is undoubtedly proving to be an effective method of prognostication and measurement of response…
Date: 23rd November 2018
CAR T-cells in myeloma: exploratory targets, payment models & treatment sequence
CAR T-cell therapy presents the opportunity to completely revolutionize the treatment of multiple myeloma, with research currently exploring the optimal…
Date: 11th October 2018
Myeloma 2017 day 2 highlights: MRD, targeted therapies and imaging advances
This is a very exciting time for multiple myeloma (MM) research, with advances in a range of areas from new…
Date: 16th November 2017
Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies
Fantastic advances in immunotherapy, including CAR T-cells, bispecific antibodies and potential immunotherapy combinations, were presented at the Myeloma 2017 meeting…
Date: 16th November 2017
Debate on the use of MRD for multiple myeloma management
The highly anticipated panel discussion on the hot topic of MRD at the Myeloma 2017 meeting in Edinburgh, UK produced…
Date: 16th November 2017